Abbott (ABT) Tops Q2 EPS by 3c; offers guidance

Abbott (NYSE: ABT) reported Q2 EPS of $1.08, $0.03 better than the analyst estimate of $1.05. Revenue for the quarter came in at $10 billion versus the consensus estimate of $9.69 billion.

GUIDANCE:

Abbott sees FY2023 EPS of $4.30-$4.50, versus the consensus of $4.40.

For earnings history and earnings-related data on Abbott (ABT) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Take-Two Interactive (TTWO) Reiterated at Buy by StoneX Ahead of November GTA VI Launch
• Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula